Profound Medical Corp.

Profound Medical Corp. develops and commercializes MRI-guided, incision-free therapies for treating diseased tissue, centered on its TULSA-PRO and Sonalleve systems. The company is organized around a holding-company structure with operating subsidiaries and serves hospitals, clinics, and physician-led treatment centers in North America, Europe, and Asia.

−254,0 %

70,8 %

−264,4 %

+50,7 %

12.52

11.17

— Profound Medical Corp.
%
TULSA-PRO systems45% MRI-guided prostate therapy systems used for incision-free ablation procedures.
Sonalleve systems20% MRI-guided ablation systems marketed mainly outside North America.
Disposable devices20% One-time-use devices consumed per patient treated on installed systems.
Clinical and service revenue15% Genius services, procedure support, warranties, and maintenance services.

Profound sells to hospitals, clinics, and other end-users that perform MRI-guided procedures, often through a mix of...

  • Hospitals and clinicsprimary

    Buy TULSA-PRO or Sonalleve systems and recurring consumables to perform MRI-guided procedures.

  • Physicians and cliniciansprimary

    Influence product adoption, procedure protocols, and ongoing clinical utilization.

  • Distributorssecondary

    Purchase and resell products in markets where Profound lacks direct sales coverage.

  • MRI scanner ecosystem partnerssecondary

    Philips, Siemens, and GE-related channels support lead generation and distribution.

Profound has generated revenue in the United States, Europe, and Asia, with the United States using a hybrid recurring...

  • •United States is a core market for TULSA-PRO commercialization
  • •Europe and Asia are important markets for system sales and consumables
  • •Outside North America, Sonalleve is marketed primarily in Europe and Asia
  • •Direct sales are supplemented by distributors where no local presence exists
  • •Compatibility with Philips, Siemens, and GE MRI scanners shapes market access

Profound’s strategy is to expand adoption of TULSA-PRO and Sonalleve by building direct sales capability, supporting...

01
Expand TULSA-PRO adoptionshort-term

Installed-base utilization and procedure volume drive recurring device and service revenue.

02
Strengthen reimbursement evidencemedium-term

Coverage by government and private payors supports broader clinical adoption.

03
Broaden commercial reach through partnershipsshort-term

MRI ecosystem partners help generate leads and reduce commercialization friction.

04
Expand product compatibility and indicationsmedium-term

Wider MRI compatibility and new applications can enlarge the addressable market.

Profound depends on physician adoption, reimbursement support, and continued regulatory clearance for its MRI-guided...

high

Physician and clinician adoption risk

The systems require clinical acceptance and procedural use to generate recurring revenue.

Scope
TULSA-PRO and Sonalleve commercialization
Materiality
high
high

Reimbursement and coverage risk

Coverage by government and private payors affects market uptake and procedure economics.

Scope
Clinical evidence and reimbursement efforts
Materiality
high
high

Single-source supplier dependence

Some components are sourced from a single supplier, creating supply and quality risk.

Scope
TULSA-PRO and Sonalleve components
Materiality
high
high

MRI compatibility and partner dependence

Commercial success depends on compatibility with select MRI scanners and partner promotion.

Scope
Philips, Siemens, and GE ecosystems
Materiality
high
medium

Distributor credit and collection risk

Open-credit sales and international distributor terms can delay or impair cash collection.

Scope
International distributor channels
Materiality
medium
Revenue recognition by product and service type
Affects quarterly revenue mix and comparability
Expected credit loss allowance
Affects receivables and bad debt expense
Quarterly mix volatility
Affects reported growth and margin patterns
Share-based compensation
Affects SG&A and R&D expense levels

Vericel Corp

VCEL · Biological Products, (No Diagnostic Substances)

ProPhase Labs, Inc.

PRPH · Pharmaceutical Preparations

Medicale Corp.

MCLE · Services-Health Services

InspireMD, Inc.

NSPR · Surgical & Medical Instruments & Apparatus

MANNKIND CORP

MNKD · Pharmaceutical Preparations

Swedish Orphan Biovitrum

SOBI.ST · Health Care

: 29.4.2026